// App-Quantinova.ai

TPS11621 : Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.

Researchers

Presenter

  • Komal L. Jhaveri

Principal Investigators

  • Juan Miguel Cejalvo

  • Lowell L. Hart

  • Dejan Juric

  • Karen Kelly

  • A. Craig Lockhart

  • Anton Melnyk

  • Kathleen N. Moore

  • John J. Nemunaitis

  • Mafalda Oliveira

  • Manish R. Patel

  • Jasgit Sachdev

  • David Smith

  • Ari Vander Walde

  • Joseph A. Ware

  • Huan Jin

  • Timothy R. Wilson

  • Michael C Wei

  • Jose Baselga

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Biomedical Research Institute INCLIVA, Valencia, Spain

  • Florida Cancer Specialists, Fort Myers, FL

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • UC Davis Comprehensive Cancer Center, Sacramento, CA

  • Washington University School of Medicine, St. Louis, MO

  • Texas Cancer Center, Abilene, TX

  • Stephenson Cancer Center, Oklahoma City, OK

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Virginia G. Piper Cancer Center at Honor Health/TGen, Scottsdale, AZ

  • Compass Oncology, Vancouver, WA

  • University of Tennessee West Cancer Center, Memphis, TN

  • Genentech, Inc., South San Francisico, CA

Locations

  • United States

  • Canada

  • Spain

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • Peptidase inhibitor 3

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Taselisib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved